主页 > 医学动态 >
【drug-news】BMS和 Sanofi赢得Plavix 官司
Posted by Jacob Goldstein
A New York judge just upheld the patent protecting Plavix, the blockbuster blood thinner co-marketed by Bristol-Myers Squibb and Sanofi-Aventis. It’s a huge — if widely expected — win for the companies, which stand to sell tens of billions of dollars worth of the drug before its patent runs out in 2011. So the obvious Next Big Question is this: What does this mean for Bristol’s chances of getting bought out?
In the first sentence of an 82-page decision, Judge Sidney Stein of the Southern District of New York wrote that Apotex “failed to prove by clear and convincing evidence that [the Plavix patent] is invalid or unenforceable on any of the grounds asserted.” The judge went on to say that Sanofi and Bristol are entitled to damages, which will be determined later.
A botched set of negotiations allowed generics manufacturer Apotex to temporarily rush generic Plavix to market last year, eating into the companies’ sale of the drug. Bristol and Sanofi sold $5.9 billion worth of Plavix in 2005, and the patent on the drug is good through 2011, WSJ.com reports.
Just last week, Bristol exited the legal purgatory of federal oversight that followed an accounting scandal. Now a major patent threat is lifted. CEO James Cornelius said earlier this year that a sale of the company was one of the strategic options he was considering. That wouldn’t be an unfamiliar move for him — he ran Guidant when it was acquired by Boston Scientific.
Sanofi has been mentioned as a possible acquirer. But Pfizer and AstraZeneca also have recently made drug deals with Bristol, and both are big enough that buying the company to boost their pipelines wouldn’t be out of the question. 股票分析师: 这是我们预料中的事
Analysts on Plavix Ruling: Just As We Expected
Posted by Jacob Goldstein
Bristol-Myers’s stock jumped more than 4% today on a federal judge’s ruling protecting the patent of Plavix, the blood-thinning drug that is the cornerstone of the company’s revenues. The success of the drug, developed and co-marketed with Sanofi-Aventis, has fueled steady speculation the companies might tie the knot, if the patent decision went their way.
A bunch of analysts who put notes out this morning suggest that both the favorable ruling and the accompanying likelihood that Bristol-Myers will be acquired were already mostly priced into the stock. If they’re right, the run-up isn’t likely to continue.
“We believe that Bristol shares already incorporate a $3 premium to our $29 fair value analysis,” writes Chris Schott of Bank of America. Morgan Stanley’s Jami Rubin comes in a little higher with a $30 target, and calls a takeout price in the mid 30s, a 15% premium to fair value. Rubin also notes that Bristol-Myers’s drug-development pacts with Pfizer and AstraZeneca could complicate a buyout — a notion also advanced by A.G. Edwards’s Joseph Tooley, who describes himself as “cool to the idea of BMY being ‘for sale.’” Tooley calls Bristol’s current valuation “lofty.”
Roopesh Patel at UBS is more bullish on the stock. He ups the price target to $35 in his note today. By his calculation, there’s an 80% probability of the company being acquired at $36. If Bristol-Myers goes it alone, the stock is worth $28 per share, according to Patel. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Bristol, Sanofi Win Plavix Case
BMS和 Sanofi赢得Plavix 官司
Posted by Jacob Goldstein
Jacob Goldstein供稿
A New York judge just upheld the patent protecting Plavix, the blockbuster blood thinner co-marketed by Bristol-Myers Squibb and Sanofi-Aventis. It’s a huge — if widely expected — win for the companies, which stand to sell tens of billions of dollars worth of the drug before its patent runs out in 2011. So the obvious Next Big Question is this: What does this mea n for Bristol’s chances of getting bought out?
纽约法官确认了专利对Plavix的保护，Plavix是百时美—施贵宝和赛诺非—安万特公司合作上市的抗凝血药。对于这两个公司来说，这是一个巨大胜利，它使这两个公司在专利到期的2011年之前可以销售价值数十亿美元的药物。因此，下面一个重要的问题就是：对百时美寻求收购的契机，这意味着什么？
In the first sentence of an 82-page decision, Judge Sidney Stein of the Southern District of New York wrote that “failed to prove by clear and convincing evidence that [the Plavix patent] is invalid or unenforceable on any of the grounds asserted.” The judge went on to say that Sanofi and Bristol are entitled to damages, which will be determined later.
在第一项长达82页的宣判中，纽约南部区域法官Sidney Stein写道：Apotex“在其所宣称的所有范围内，没有清晰、有说服力的证据证明Plavix的专利无效或不能执行”，法官还说，稍后将确定Sanof和Bristol公司的赔偿金。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-05 05:11
医学,生命科学网